Stay informed about ZOLGENSMA and SMA

Spinal muscular atrophy (SMA) can be a life-threatening condition and needs to be diagnosed quickly so treatment can be started immediately. Stay informed about ZOLGENSMA^® (onasemnogene abeparvovec-xioi) and SMA to help in your decision about treatment. Sign up today and receive information about:

How ZOLGENSMA works
Results from the clinical studies of ZOLGENSMA
Support available through the OneGene Program^®
Navigating life with SMA after treatment with resources from Every Day With SMA

All fields are required.

By submitting this form, I authorize Novartis Gene Therapies, Inc., and companies working with Novartis Gene Therapies, to contact me by mail, email, and telephone for marketing purposes or to otherwise provide me with information about Novartis Gene Therapies products, services, and programs or other topics of interest; conduct market research; or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that any information that I provide may be used by Novartis Gene Therapies to help develop new products, services, and programs. I understand that my consent is not required as a condition of purchasing or receiving any goods or services from Novartis Gene Therapies. I understand that I may revoke this authorization and choose not to receive information from Novartis Gene Therapies by clicking the “unsubscribe” link provided in emails I receive from Novartis Gene Therapies. I have read and understand the Privacy Policy.

Important Safety Information

What is the most important information I should know about ZOLGENSMA?

ZOLGENSMA can increase liver enzyme levels and cause acute serious liver injury or acute liver failure.
Patients will receive an oral corticosteroid before and after infusion with ZOLGENSMA and will undergo regular blood tests to monitor liver function.

Important Safety Information

What is the most important information I should know about ZOLGENSMA?

ZOLGENSMA can increase liver enzyme levels and cause acute serious liver injury or acute liver failure.
Patients will receive an oral corticosteroid before and after infusion with ZOLGENSMA and will undergo regular blood tests to monitor liver function.
Contact the patient’s doctor immediately if the patient’s skin and/or whites of the eyes appear yellowish, if the patient misses a dose of corticosteroid or vomits it up, or if the patient experiences a decrease in alertness.

What should I watch for before and after infusion with ZOLGENSMA?

Infections before or after ZOLGENSMA infusion can lead to more serious complications. Contact the patient’s doctor immediately if you see any signs of a possible infection such as coughing, wheezing, sneezing, runny nose, sore throat, or fever.
Decreased platelet counts could occur following infusion with ZOLGENSMA. Seek immediate medical attention if the patient experiences unexpected bleeding or bruising.
Thrombotic microangiopathy (TMA) has been reported to occur approximately one week after ZOLGENSMA infusion. Caregivers should seek immediate medical attention if the patient experiences any signs or symptoms of TMA, such as unexpected bruising or bleeding, seizures, or decreased urine output.

What do I need to know about vaccinations and ZOLGENSMA?

Talk with the patient’s doctor to decide if adjustments to the vaccination schedule are needed to accommodate treatment with a corticosteroid.
Protection against respiratory syncytial virus (RSV) is recommended.

Do I need to take precautions with the patient’s bodily waste?

Temporarily, small amounts of ZOLGENSMA may be found in the patient’s stool. Use good hand hygiene when coming into direct contact with bodily waste for 1 month after infusion with ZOLGENSMA. Disposable diapers should be sealed in disposable trash bags and thrown out with regular trash.

What are the possible or likely side effects of ZOLGENSMA?

The most common side effects that occurred in patients treated with ZOLGENSMA were elevated liver enzymes and vomiting.

Indication

What is ZOLGENSMA?
ZOLGENSMA is a prescription gene therapy used to treat children less than 2 years old with spinal muscular atrophy (SMA). ZOLGENSMA is given as a one-time infusion into a vein. ZOLGENSMA was not evaluated in patients with advanced SMA.

The safety information provided here is not comprehensive. Talk to the patient’s doctor about any side effects that bother the patient or that don’t go away.

You are encouraged to report suspected side effects by contacting the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch, or Novartis Gene Therapies, Inc. at 833-828-3947.

Please see the Full Prescribing Information.